CC
CTNM

Casdin Capital’s Contineum Therapeutics CTNM Stock Holding History

Casdin Capital’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.94M Hold
148,333
– – 0.15% 36
2025
Q4 		$1.7M Hold
148,333
– – 0.11% 33
2025
Q3 		$1.74M Hold
148,333
– – 0.15% 26
2025
Q2 		$589K Hold
148,333
– – 0.05% 30
2025
Q1 		$1.04M Sell
148,333
-148,333
-50% -$1.35M 0.08% 37
2024
Q4 		$4.35M Hold
296,666
– – 0.29% 31
2024
Q3 		$5.68M Hold
296,666
– – 0.38% 26
2024
Q2 		$5.22M Buy
+296,666
New +$4.78M 0.4% 26

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Casdin Capital's CTNM Position: Q1 2026 in Review

Casdin Capital held its Contineum Therapeutics (CTNM) position steady in Q1 2026 at 148,333 shares worth $1.94M. The position accounts for 0.15% of the portfolio, ranked #36.

Casdin Capital first reported a position in CTNM in Q2 2024 and has held it in 8 quarters since. The position peaked at $5.68M in Q3 2024. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • Casdin Capital held 148,333 shares of Contineum Therapeutics worth $1.94M as of Q1 2026.
  • Casdin Capital left its Contineum Therapeutics share count unchanged in Q1 2026.
  • Contineum Therapeutics made up 0.15% of Casdin Capital's portfolio in Q1 2026, its #36 holding.
  • Casdin Capital first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Casdin Capital's Contineum Therapeutics position peaked at $5.68M in Q3 2024.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Casdin Capital's 13F filing for Q1 2026, filed 15 May 2026.